# Quanta Therapeutics Reports 25% Response Rate for QTX3034 Combination in KRAS G12D Colorectal Cancer at ESMO 2026 > Quanta Therapeutics reported a 25% overall response rate for QTX3034 plus cetuximab in KRAS G12D colorectal cancer at ESMO 2026. - Published: 2026-10-24T13:01:21+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-10-24/quanta-therapeutics-qtx3034-esmo-colorectal-cancer - Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/24/3387679/0/en/quanta-presents-positive-clinical-combination-data-in-kras-g12d-mutant-crc-at-esmo-and-highlights-pan-kras-progress.html) ## Key takeaways - QTX3034 plus cetuximab produced a 25% overall response rate and 75% disease control rate in 21 patients with refractory KRAS G12D-mutant colorectal cancer. - Adding FOLFOX chemotherapy to the combination produced a 50% overall response rate and 90% disease control rate in 11 patients. - Quanta Therapeutics plans an Investigational New Drug filing for pan-KRAS inhibitor QTX6255 in the fourth quarter of 2026, with a Phase 1 trial anticipated in early 2027. [Quanta Therapeutics](https://akta.pro/company-profiles/0000mqg/quanta-therapeutics) reported a 25% overall response rate and 75% disease control rate for its oral KRAS G12D inhibitor QTX3034 combined with cetuximab in patients with KRAS G12D-mutant colorectal cancer. The privately held, clinical-stage biopharmaceutical company announced the data on October 24, 2026, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/24/3387679/0/en/quanta-presents-positive-clinical-combination-data-in-kras-g12d-mutant-crc-at-esmo-and-highlights-pan-kras-progress.html). ## QTX3034 Data From the ESMO Session Quanta presented the Phase 1 data during a rapid oral session at the European Society for Medical Oncology Congress 2026, held October 23 to 27 in Madrid, Spain. The QTX3034-cetuximab combination was tested in 21 patients with refractory colorectal cancer, producing 5 partial responses, 2 of them unconfirmed, with responses lasting up to 5.5 months. QTX3034 at 800 mg or 1200 mg twice daily with mFOLFOX6 chemotherapy was tested in 11 patients, a primarily chemo-refractory group, producing a 50% overall response rate, 90% disease control rate, 4 partial responses, 1 of them unconfirmed, and 1 complete response in a chemotherapy-naive patient, with ongoing responses up to 3.9 months. The data used an August 31, 2026 cutoff. Quanta said the cetuximab combination was generally well tolerated, with primarily low-grade, manageable adverse events and low rates of dose modifications or discontinuations. The company said adding FOLFOX showed no new safety signals at either QTX3034 dose level. "These new clinical data highlight the potential of QTX3034-based combinations to achieve deep tumor responses and improve disease control for patients with KRAS G12D-mutant colorectal cancer," said Dr. Ignacio Garrido-Laguna, MD, PhD, Principal Investigator at Moffitt Cancer Center. ## Quanta's Funding and Pipeline Records Quanta Therapeutics is a clinical-stage biopharmaceutical company developing orally bioavailable allosteric small-molecule inhibitors of KRAS G12D and G12V for RAS-driven cancers including pancreatic, colorectal, lung, and endometrial tumors, according to [akta.pro company records](https://akta.pro/company-data). The same records show the company has raised $166.2 million in total funding, most recently a Series D round dated May 22, 2023, and carries a valuation estimate of $250 million to $500 million. Quanta has three KRAS inhibitor programs in clinical development: QTX3034, QTX3046, and QTX3544. ## Other ESMO and Colorectal Cancer Readouts Johnson & Johnson presented first clinical data for its prostate cancer drug JNJ-6143 at ESMO 2026, including safety and efficacy findings, [The future of trading](https://capital.com/en-int/news/johnson-johnson-unveils-first-clinical-data-for-prostate-cancer) reported on October 23, 2026. Bold Therapeutics reached the midpoint of its randomized Phase 2 BOLD-100-001 trial in second-line metastatic colorectal cancer, enrolling 60 of 120 planned patients, [PR Newswire](https://www.prnewswire.com/news-releases/bold-therapeutics-reaches-enrollment-midpoint-in-randomized-phase-2-trial-of-bold-100-in-second-line-metastatic-colorectal-cancer-302909446.html) reported on October 15, 2026. ## QTX6255 Filing Timeline Quanta said QTX6255, a pan-KRAS inhibitor, is on track for an Investigational New Drug application filing in the fourth quarter of 2026, with a Phase 1 clinical trial anticipated to begin in early 2027. The company said a recently completed Series D extension financing funds operations through key clinical data readouts for QTX6255. ## Companies in this story - [Quanta Therapeutics company profile](https://akta.pro/company-profiles/0000mqg/quanta-therapeutics) · website: https://www.quantatx.com --- News for Agent · https://newsforagent.com/llms.txt